Table 1 Baseline characteristics of the subjects according to their diabetes status at the end of the follow-up
From: Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes
Parameters | All (n = 307) | No diabetes (n1 = 192) | Diabetes (n2 = 115) | Available data (n1/n2) |
|---|---|---|---|---|
Clinical data | ||||
Age (y) | 57.3 ± 9.9 | 57.2 ± 10.4 | 57.5 ± 9.0 | 192/115 |
Sex (female) | 92 (30.0%) | 54 (28.1%) | 38 (33.0%) | 192/115 |
BMI (kg/m2) | 29.8 ± 6.2 | 28.8 ± 5.9 | 31.4 ± 6.3 | 192/115 |
Waist circumference (cm) | 99 ± 14.6 | 96.8 ± 14.0 | 102.7 ± 14.9 | 191/114 |
Hip circumference (cm) | 105.2 ± 13.1 | 103.4 ± 11.2 | 108.2 ± 15.3 | 188/112 |
Waist/hip circumference ratio | 0.94 ± 0.09 | 0.93 ± 0.09 | 0.95 ± 0.09 | 188/112 |
Statin use | 70 (22.8%) | 42 (21.9%) | 28 (24.3%) | 192/115 |
Fibrate use | 11 (3.6%) | 5 (2.6%) | 6 (5.2%) | 192/115 |
Ezetimibe use | 2/307 (0.7%) | 0/192 (0%) | 2/115 (1.7%) | 192/115 |
Glucose homeostasis | ||||
FPG (mg/dL) | 115 [112; 119] | 114 [112; 118] | 116 [113; 121] | 192/115 |
HbA1c (%) | 5.9 [5.6; 6.2] | 5.8 [5.5; 6.0] | 6.0 [5.8; 6.3] | 191/115 |
Insulin (mIU/L) | 14.1 ± 9.1 | 12.4 ± 8.1 | 17.1 ± 9.9 | 182/103 |
HOMA-IR | 4.02 ± 2.69 | 3.46 ± 2.39 | 5.01 ± 2.90 | 182/103 |
HOMA-β (%) | 100.6 ± 65.9 | 92.9 ± 61.5 | 114.1 ± 71.3 | 182/103 |
Adiponectin (µg/L) | 3.70 ± 2.20 | 3.95 ± 2.30 | 3.28 ± 1.91 | 183/103 |